PT  - JOURNAL ARTICLE
AU  - Ji, Xiangwen
AU  - Zhang, Hongwei
AU  - Cui, Qinghua
TI  - A panel of synapse assembly genes as a biomarker for Gliomas
AID  - 10.1101/19011114
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 19011114
4099  - http://medrxiv.org/content/early/2019/11/04/19011114.short
4100  - http://medrxiv.org/content/early/2019/11/04/19011114.full
AB  - Gliomas are the most common primary brain cancers. In recent years, IDH mutation and 1p/19q codeletion have been suggested as biomarkers for the diagnosis, treatment and prognosis of gliomas. However, these biomarkers are only effective for a part of glioma patients and thus more biomarkers are still emergently needed. Recently, an electrochemical communication between normal neurons and glioma cells by neuro-glioma synapse has been reported. Moreover, it was discovered that breast-to-brain metastasis tumor cells have pseudo synapses with neurons and these synapses were indicated to promote tumor progression and metastasis. Based on the above observations, we first curated a panel of 66 SA genes and then proposed a metric, SA score, to quantify the synapseness for each sample of 12 glioma gene expression datasets from TCGA, CGGA, and GEO. Strikingly, SA score showed excellent predictive ability for the prognosis, diagnosis, and grading of gliomas. Moreover, being compared with the two established biomarkers, IDH mutation and 1p/19q codeletion, SA score was demonstrated independent and better predictive performance. In conclusion, this study revealed that SA genes contribute to glioma formation and development, and proposed a quantitative method, SA score, as an efficient biomarker for monitoring gliomas.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the grants from the Natural Science Foundation of China (81670462, 81970440, and 81921001 to QC).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets supporting the conclusions of this article are available in TCGA repository, https://portal.gdc.cancer.gov/, the FireBrowse repository, http://firebrowse.org/, the CGGA repository, http://www.cgga.org.cn/ and GEO repository, https://www.ncbi.nlm.nih.gov/gds/. WHO grade, IDH mutation status and 1p/19q codeletion status of TCGA are available in the supplementary file of the published article by Ceccarelli et al, https://doi.org/10.1016/j.cell.2015.12.028. The 66 SA genes are available in the supplementary file 1. https://portal.gdc.cancer.gov/ http://firebrowse.org/ http://www.cgga.org.cn/ https://www.ncbi.nlm.nih.gov/gds/ https://doi.org/10.1016/j.cell.2015.12.028